Submitted:
03 June 2023
Posted:
06 June 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
Statistical data Processing
3. Results
3.1. Type of Surgical Revascularisation and Basic Parameters
| ECB (N = 51) | off ECB (N = 49) | t * ili χ2 ** ili Z *** (p) | ||
|---|---|---|---|---|
| Age | 63.90 ± 7.49 | 65.39 ± 7.48 | 0.992 (0.323) * | |
| Gender (male) | 39 (76.5%) | 39 (79.6%) | 0.018 (0.811) ** | |
| CABG | I | 9 (17.6%) | 34 (69.4%) |
35.834 (0.000) ** 5.916 (0.000) *** |
| II | 22 (43.1%) | 15 (30.6%) | ||
| III | 20 (39.2%) | 0 (0.0%) | ||
| RBC (1 × 1012/L) | 4.45 ± 0.46 | 4.49 ± 0.49 | 0.376 (0.707) * | |
| HGB (g/L) | 136.80 ± 11.68 | 138.80 ± 10.25 | 0.905 (0.368)* | |
| HCT (%) | 38.78 ± 4.48 | 39.58 ± 3.80 | 0.965 (0.337) * | |
| WBC (1 × 109/L) | 7.34 ± 1.51 | 6.95 ± 1.13 | 1.431 (0.156) * | |
| PLT (1 × 109/L) | 241.72 ± 70.05 | 232.51 ± 56.70 | 0.721 (0.472) * | |
| CRP (ng/mL) | 9.0 (4.0–14.0) | 10.0 (5.0–13.0) | 0.252 (0.801) *** | |
| PSEP (pg/mL) | 246.0 (167.0–366.0) | 235.0 (166.0–337.0) | 0.538 (0.591) *** | |
| PSEP (≥600 pg/mL) | 0 (0.0%) | 0 (0.0%) | ||
3.2. Influence of Extracorporeal Circuit on Basic Postoperative Parameters
| ECB (N = 51) | off ECB (N = 49) | t * ili Z ** (p) | |
|---|---|---|---|
| Absolute differencies | |||
| WBC (1 × 109/L) | 3.8 (0.1–6.2) | 2.2 (−0.2–5.2) | 1.393 (0.164) ** |
| CRP (ng/mL) | 100.0 (89.0–119.0) | 79.0 (68.0–98.0) | 4.072 (0.000) ** |
| PSEP (pg/mL) | 200.0 (104.0–377.0) | 109.0 (59.0–189.5) | 3.427 (0.001) ** |
| Relative changes | |||
| WBC (1 × 109/L) | 1.47 ± 0.45 | 1.37 ± 0.53 | 1.051 (0.296) * |
| CRP (ng/mL) | 11.6(9.1–23.8) | 9.9 (5.6–18.3) | 1.486 (0.137) ** |
| PSEP (pg/mL) | 1.9 (1.5–2.5) | 1.5 (1.2–2.0) | 2.748 (0.006) ** |
3.3. Cytokines Response
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Wijns, W.; Kolh, P.; Danchin, N.; et al. Guidelines on myocardialrevascularization: The Task Force on Myocardial Revascularization of the European Society ofCardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010, 31, 2501–2555. [Google Scholar] [PubMed]
- Welsby, I.J.; Bennett-Guerrero, E.; Atwell, D.; et al. The association of complication type with mortality and prolonged stay after cardiac surgery with cardiopulmonary bypass. Anesth Analg 2002, 94, 1072–1078. [Google Scholar] [CrossRef] [PubMed]
- Fitch, J.C.; Rollins, S.; Matis, L.; Alford, B.; Aranki, S.; Collard, C.D.; Dewar, M.; Elefteriades, J.; Hines, R.; Kopf, G.; Kraker, P.; Li, L.; O’Hara, R.; Rinder, C.; Rinder, H.; Shaw, R.; Smith, B.; Stahl, G.; Shernan, S.K. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999, 100, 2499–2506. [Google Scholar] [CrossRef] [PubMed]
- Day, J.R.; Taylor, K.M. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg 2005, 3, 129–140. [Google Scholar] [CrossRef] [PubMed]
- Lam, N.Y.; Rainer, T.H.; Chan, L.Y.; et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem 2003, 49, 1286–1291. [Google Scholar] [CrossRef] [PubMed]
- Ohri, S.K.; Bowles, C.W.; Mathie, R.T.; et al. Effect of cardiopulmonary bypass perfusion protocols on gut tissue oxygenation and blood flow. Ann Thorac Surg 1997, 64, 163–170. [Google Scholar] [CrossRef] [PubMed]
- Byhahn, C.; Strouhal, U.; Martens, S.; et al. Incidence of gastrointestinal complications in cardiopulmonary bypass patients. World J Surg 2001, 25, 1140–1144. [Google Scholar] [CrossRef] [PubMed]
- Junichi, S.; Eiji, H.; Akio, M.; Tomoyuki, K.; Hidetomo, N.; Kazuyoshi, H. Pilot Study of Changes in Presepsin Concentrations Compared With Changes in Procalcitonin and C-Reactive Protein Concentrations After Cardiovascular Surgery. J Cardiothorac Vasc Anesth 2017, 31, 1262–1267. [Google Scholar]
- Popov, D.; Plyushch, M.; Ovseenko, S.; Abramyan, M.; Podshchekoldina, O.; Yaroustovsky, M. Prognostic value of sCD14-ST (presepsin) in cardiac surgery. Kardiochir Torakochirurgia Pol 2015, 12, 30–36. [Google Scholar] [PubMed]
- Sablotzki, A.; Mann, V.; Simm, A.; Czeslick, E. Changes in the cytokine network through escalating SIRS after heart surgery. Anasthesiol Intensivmed Notfallmed Schmerzther 2001, 36, 552–559. [Google Scholar] [CrossRef] [PubMed]
- Clin Exp Immunol 1999, 118, 242–246. [CrossRef]
- Perioperative serum levels of tumour-necrosis-factor alpha (TNF-α), IL-1β, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution. Roth-Isigkeit, A.; Borstel, T.V.; Seyfarth, M.; Schmucker, P..
- Diegeler, A.; Doll, N.; Rauch, T.; Haberer, D.; Walther, T.; Falk, V.; et al. Humoral immune response during coronary artery bypass grafting: a comparison of limited approach, “off-pump” technique, and conventional cardiopulmonary bypass. Circulation 2000, 102, III95–III100. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, K.; Miyamoto, H.; Suzuki, K.; Horikoshi, S.; Arai, T.; Kurosawa, H. Evidence of organ damage after cardiopulmonary bypass. The role of elastase and vasoactive mediators. J Thorac Cardiovasc Surg 1992, 104, 666–673. [Google Scholar] [CrossRef] [PubMed]
- Kukielka, G.L.; Smith, C.W.; LaRosa, G.J.; et al. Interleukin8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995, 95, 89–103. [Google Scholar] [CrossRef] [PubMed]
- Oz, M.C.; Liao, H.; Naka, Y.; et al. Ischemia-induced interleukin-8 release after human heart transplantation. A potential role for endothelial cells. Circulation 1995, 92, 428–432. [Google Scholar] [CrossRef] [PubMed]
- Wan, S.; LeClerc, J.L.; Schmartz, D.; Barvais, L.; Huynh, C.H.; Devière, J.; DeSmet, J.M.; Vincent, J.L. Hepatic release of interleukin-10 during cardiopulmonary bypass in steroid-pretreated patients. Am Heart J 1997, 133, 335–339. [Google Scholar] [CrossRef] [PubMed]

| ECB (N = 51) | off ECB (N = 49) | t * ili χ2 ** ili Z *** (p) | |
|---|---|---|---|
| RBC (1 × 1012/L) | 3.9 (3.6–4.3) | 3.7 (3.5–4.0) | 1.880 (0.060) *** |
| HGB (g/L) | 115.0 (110.0–119.0) | 114.0 (108.5–116.0) | 1.693 (0.090) *** |
| WBC (1 × 109/L) | 10.76 ± 3.69 | 9.34 ± 3.56 | 1.960 (0.053) * |
| PLT (1 × 109/L) | 154.67 ± 59.75 | 141.33 ± 53.00 | 1.179 (0.241) * |
| CRP (ng/mL) | 110.0 (90.0–132.0) | 92.0 (76.5–104.5) | 3.552 (0.000) *** |
| PSEP (pg/mL) | 419.0 (315.0–625.0) | 343.0 (300.0–419.5) | 2.552 (0.011) *** |
| PSEP (≥600 pg/mL) | 14 (27.5%) | 2 (4.1%) | 8.490 (0.002) ** |
| Before surgery (20) | After surgery (20) | t * ili Z ** (p) | ||
|---|---|---|---|---|
| TNFα | off ECB | 239.8 | 245.1 | 0.69 * |
| TNFα | ECB | 263.01 | 270.64 | 0.502 * |
| IL-2 | off ECB | 46.56 | 68.73 | 0.001 *, 0.01 ** |
| IL-2 | ECB | 46.00 | 74.32 | 0.006 *, 0.01 ** |
| IL-1β | off ECB | 20.45 | 36.70 | 0.01 ** |
| IL-1β | ECB | 17.57 | 32.88 | 0.000 ** |
| Il-6 | off ECB | 130.0 | 868.16 | 0.00 * 0.01 ** |
| Il-6 | ECB | 83.23 | 901.28 | 0.00 *, 0.000 ** |
| IL-10 | off ECB | 34.13 | 123.13 | 0.00 * 0.00 ** |
| IL-10 | ECB | 29.63 | 153.57 | 0.81 *, 0.00 ** |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).